
PROJECT NUMBER

22742

ThrEDs - A new regenerative, engineerable modality for reversing fibrosis

ThrEDs are thrombospondin rich particles with a core of ECM proteins that have been demonstrated to reverse fibrotic phenotypes in wound healing and Dupuytren's disease, by engaging both cellular and ECM targets.

Applications: Antifibrotic therapeutics, wound healing, tissue regeneration, targeted drug delivery, engineered nanoparticles





Features	Benefits
Reverses fibrotic cellular phenotypes	Disease-modifying treatment for fibrosis rather than merely slowing progression
Acts on both cells and the extracellular matrix	Targets multiple drivers of fibrosis to promote restoration of tissue homeostasis
Accelerates cellular migration and wound closure	Enhance tissue repair and regenerative processes
Genetically engineerable protein shell	Enables development of customised, targeted therapeutic nanoparticles
Naturally occurring, non-vesicular nanoparticle structure	Offers a differentiated therapeutic platform with established laboratory isolation methods

Patented and Available for

- Co-development
- Consulting
- Licensing

To find out more, contact enquiries@innovation.ox.ac.uk and quote the project number.

The above information is provided ‘as is’ without conditions or warranties. Oxford University Innovation makes no representation and gives no warranty that it is the owner of the intellectual property rights in the technology described. © Oxford University Innovation Ltd 2026, Buxton Court, 3 West Way, Oxford, OX2 0JB.